Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma

    NEXT STORY
    Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors APMA Annual Scientific Meeting
    PREV STORY
    Advanced Wound Dressings Market to Reach US$ 8,460.8 Mn by 2025, Increasing FDA Approvals to Enable Growth, says Fortune Business Insights
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas

    author_avatar
    NASDAQ Market News

    Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2018 Financial Results

    author_avatar
    NASDAQ Market News

    VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate

    CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), ...

    author_avatar
    NASDAQ Market News